Mass spectrometry could solve pharma riddle
Pharma researchers could gain from mass spectrometry-based studies

Bioanalytical

Mass spectrometry could solve pharma riddle

15 Jun, 2010

Published over 16 years ago. See the latest and most current information on Bioanalytical.

The riddle of what happens at the carboxy-termini of protein clippings has puzzled pharma professionals for some time.

While the amino-termini of protein clippings have been successfully analysed, pharma researchers have thus far failed to find a satisfactory way to investigate the clippings' other ends.

However, mass spectrometry may provide the answer, as scientists at Albert-Ludwigs-Universitaet Freiburg have revealed.

The discovery could hold promise for the research of medical conditions - such as the role of cathepsin proteases in cancer development.

Using mass spectrometry as part of a multi-stage process, the scientists identified carboxy-terminal sequences following proteolysis.

They claim to have unearthed a relatively high rate of proteolysis, as 40 per cent of carboxy-termini identified are believed to have been created through molecular cleavage.

The University recently hosted a conference of about 350 scientists who discussed issues relating to systems biology and, in particular, generalising research at the cellular level to be applied to whole mammalian organisms.

Latest News

Explore Our Other Sites

Labmate Online
Single medium supports both 2D and 3D pluripotent stem cell culture and growth
Explore more Arrow
Envirotech Online
Peristaltic pumps for high-purity oxygen applications
Explore more Arrow
Pollution Solutions Online
Vacuum technology enables efficient lithium-ion battery recycling with recovery rates of up to 95%
Explore more Arrow
Petro Online
The expanding role of high-temperature, high-shear viscometry in modern engine oil development
Explore more Arrow